{"id":250906,"date":"2022-06-03T00:00:00","date_gmt":"2022-06-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidop0031-biopharma-lebers-hereditary-optic-neuropathy-epidemiology-2\/"},"modified":"2026-05-12T11:29:33","modified_gmt":"2026-05-12T11:29:33","slug":"epidop0031-biopharma-lebers-hereditary-optic-neuropathy-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0031-biopharma-lebers-hereditary-optic-neuropathy-epidemiology-mature-markets\/","title":{"rendered":"Leber&#8217;s Hereditary Optic Neuropathy &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of Leber\u2019s hereditary optic neuropathy (<abbr title=\"Leber\u2019s hereditary optic neuropathy \">LHON<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"Leber\u2019s hereditary optic neuropathy \">LHON<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"Leber\u2019s hereditary optic neuropathy \">LHON<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Leber\u2019s hereditary optic neuropathy \">LHON<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts three <abbr title=\"Leber\u2019s hereditary optic neuropathy \">LHON<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases.<\/li>\n<li>Diagnosed prevalent cases by gene mutation.<\/li>\n<li>Drug-treatable prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250906","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ophthalmology","biopharma-product-epidemiology","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250906\/revisions"}],"predecessor-version":[{"id":283269,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250906\/revisions\/283269"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}